After editing the GATA binding protein 1 (GATA1) binding site in the BCL11A enhancer +58 using the Cas9 RNP complex to reduce BCL11A expression and increase fetal γ‐globin, the HbF level in patients with SCD increased from 13.9 to 47.5%, indicating that the gene editing resulted in long‐lasting HbF induction, and CIRCLE‐seq (Circularization for In vitro Reporting of CLeavage Effects by Sequencing) did not detect off‐target activity.243. Here, BCL11A is linked to Schnyder corneal dystrophy.